Symbicort

Report
30 Pages
July 2018
Region: Global
Citeline
ID: 4533482

Drug Overview
AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting with approval for asthma. This was followed by approval for chronic obstructive pulmonary disease in the EU in 2003 and in the US in February 2009. In Japan, where Symbicort is co-promoted by Astellas and AstraZeneca, the drug received approval in August 2012. Budesonide is an ICS that exhibits potent glucocorticoid activity, and formoterol is a LABA that acts locally in the lungs as a bronchodilator.

OVERVIEW

Drug Overview
Product Profiles
Symbicort: Chronic obstructive pulmonary disease (COPD)
Symbicort: Asthma

LIST OF FIGURES

Figure 1: Symbicort for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Symbicort for COPD
Figure 3: The authors drug assessment summary of Symbicort for COPD
Figure 4: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Symbicort for asthma – SWOT analysis
Figure 6: The authors drug assessment summary of Symbicort in asthma
Figure 7: The authors drug assessment summary of Symbicort in asthma
Figure 8: Symbicort sales for asthma across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Symbicort drug profile
Table 2: Overview of pivotal trial data for Symbicort in COPD
Table 3: Symbicort sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Symbicort drug profile
Table 5: Symbicort pivotal trial data in asthma
Table 6: Symbicort late-phase trial data in asthma
Table 7: Symbicort sales for asthma in the US, Japan, and five major EU markets, by country ($m), 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9608EUR$10,000USD£8,215GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47081EUR$49,000USD£40,252GBP

Table of Contents

Related Topics

Related Reports

Pulmonary Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Emphysema Treatment Global Market Report 2024

Global Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Forecast 2023-2030

Global Cystic Fibrosis Market Analysis & Forecast to 2024-2034

Advances in Combination Therapy for Asthma and COPD. Edition No. 1